In addition, random allocation to 20 mg of daily rosuvastatin significantly reduced AF risks within the JUPITER (justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin) trial, which was conducted in the United States on patients with underlying inflammation (CRP higher than 2 mg/L, without high low-density lipoprotein) [56]. The gene discussed is CRP; the disease is atrial fibrillation.